More MS news articles for Dec 2001

Current Trials - Trials Recruiting Patients, Indexed by State

http://www.nationalmssociety.org/Research-trialsrecruiting.asp

This list contains information about trials that are recruiting people with MS, which was provided to us by the investigators involved. Although we try to keep this list current, it is possible that the trials are no longer enrolling participants. More information on trials recruiting patients is available from the MS Quarterly Report's listing of Current Clinical Trials in MS.

For definitions and abbreviations, see the Glossary, and see Clinical Trial Participation for general information on enrolling in trials. Individuals who are interested in participating in a clinical trial are encouraged to discuss the possibility with their personal physicians.

Please note: To participate, you will have to reside near the facility, as treatment and follow-up visits will be necessary throughout the course of the study. Also, please keep in mind that clinical trials often have strict criteria for enrollment, specifying the type of people (disease type, duration, age, etc.) they are seeking to participate. These help to ensure that the results will be as reliable and as effective as possible.

Multiple States, Centers
 
Agent: Novantrone® (mitoxantrone for injection concentrate)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study to determine tolerability
Institution(s): Multiple sites
Type of MS: Worsening RR, SP
Number of Subjects: 500
Funding: Immunex Corporation
Enrollment Information: goodkind@immunex.com
Agent: Novantrone and Avonex® (interferon beta-1a) or Copaxone® (glatiramer acetate)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study to determine tolerability of combining Novantrone with either Avonex or Copaxone
Institution(s): Multiple sites
Type of MS: Worsening RR, SP
Number of Subjects: 60
Funding: Immunex Corporation
Enrollment Information: goodkind@immunex.com
Agent: Investigational drug approved for treatment of mild to moderate Alzheimer’s disease; name of drug not released
Treatment Mode of Action: To treat cognitive impairment
Study Description/Purpose: Blinded, placebo-controlled study to test ability to treat cognitive 
Institution(s): impairment in MS
Type of MS: Multiple sites
Number of Subjects: All types
Funding: 240
Enrollment Information: 1-866-812-8547, see related bulletin

California
 
Agent: Androgel™ (testosterone gel)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study for treatment of MS
Institution(s): University of California, Los Angeles
Type of MS: Definite RR or SP, with at least 1 relapse in 2 years prior to entry in study
Number of Subjects: 12 males
Funding: none
Enrollment Information: Ricki Klutch, RN, rklutch@ucla.edu

Connecticut
 
Agent: Zocor® (simvastatin), a cholesterol-lowering drug under study for treatment of MS
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study to determine effectiveness
Institution(s): Yale MS Research Center, New Haven, and others
Type of MS: RR
Number of Subjects: not available
Funding: Merck, Inc.
Enrollment Information: msresearch@yale.edu
Agent: Schwann cell (myelin-making cells from peripheral nervous system) transplantation
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Blinded study of safety and effectiveness
Institution(s): Yale MS Research Center, New Haven
Type of MS: SP
Number of Subjects: 5
Funding: The Myelin Project
Enrollment Information: msresearch@yale.edu

Maine
 
Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind, placebo-control study for treatment of MS
Institution(s): Dartmouth Medical School, Hanover, NH
Type of MS: RR
Number of Subjects: 40-48
Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke
Enrollment Information: kathleen.ryan@dartmouth.edu

Maryland
 
Agent: Betaseron® (interferon beta 1-b) and Imuran® (azathioprine)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study of safety and effectiveness of combination therapy
Institution(s): University of Maryland, Baltimore, and others
Type of MS: RR, SP
Number of Subjects: 18
Funding: Berlex Laboratories, Inc.
Enrollment Information: pcala001@umaryland.edu

Massachusetts
 
Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind, placebo-control study for treatment of MS
Institution(s): Dartmouth Medical School, Hanover, NH
Type of MS: RR
Number of Subjects: 40-48
Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke
Enrollment Information: kathleen.ryan@dartmouth.edu

Michigan
 
Agent: Rebif® (interferon beta-1a), Rebiject™ Mini (autoinjector device)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study comparing the tolerability of Rebif injections with and without the use of Rebiject™ Mini in people with relapsing-remitting MS.
Institution(s): University of Michigan, Ann Arbor, and others
Type of MS: RR
Number of Subjects: No limit
Funding: Serono S.A.
Enrollment Information: dmiko@umich.edu

Missouri
 
Agent: trimethoprim (antibiotic therapy) and vitamin C
Treatment Mode of Action: To prevent MS relapse with bladder care
Study Description/Purpose: Double-blind, placebo-control study to compare the number of MS relapses in people who receive routine bladder care and those receiving placebo
Institution(s): Washington University, St. Louis
Type of MS: RR, SP
Number of Subjects: 100 females
Funding: National MS Society
Enrollment Information: lauberj@neuro.wustl.edu
Agent: Avonex and intravenous high dose methotrexate
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study of safety and effectiveness of combination therapy
Institution(s): Consultants in Neurology and MidAmerican Neuroscience Institute, Kansas City
Type of MS: worsening RR, and SP
Number of Subjects: 15
Funding: Biogen, Inc.
Enrollment Information: Ldressman@cinpc.com

New Hampshire
 
Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind, placebo-control study for treatment of MS
Institution(s): Dartmouth Medical School, Hanover
Type of MS: RR
Number of Subjects: 40-48
Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke
Enrollment Information: Enrollment Information: kathleen.ryan@dartmouth.edu

New York
 
Agent: Copaxone
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study comparing effectiveness in people who have never been treated with Copaxone and people who have not responded to interferon therapy
Institution(s): Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for MS, New York City
Type of MS: RR
Number of Subjects: 120
Funding: Teva Marion Partners
Enrollment Information: Michele Weber, (212) 241-4264

Ohio
 
Agent: intensive outpatient rehabilitation
Treatment Mode of Action: To improve symptoms following acute relapses of MS
Study Description/Purpose: Blinded, controlled study to determine effectiveness of physical and occupational therapy following acute relapses of MS
Institution(s): Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland
Type of MS: RR and SP, following acute relapses
Number of Subjects: 160
Funding: National MS Society
Enrollment Information: ivancid@ccf.org

South Carolina
 
Agent: Zocor® (simvastatin), a cholesterol-lowering drug under study for treatment of MS
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Open-label study to determine effectiveness 
Institution(s): Medical University of South Carolina, Charleston, and others
Type of MS: RR
Number of Subjects: not available
Funding: Merck, Inc.
Enrollment Information: William R. Tyor, MD, tyorwr@musc.edu

Vermont
 
Agent: IDEC-131 (anti-CD40L or anti-CD154, molecule that regulates immune response)
Treatment Mode of Action: To affect immune function
Study Description/Purpose: Double-blind, placebo-control study for treatment of MS
Institution(s): Dartmouth Medical School, Hanover, NH
Type of MS: RR
Number of Subjects: 46-50
Funding: Immune Tolerance Network, National Institute of Neurological Disorders and Stroke
Enrollment Information: kathleen.ryan@dartmouth.edu

International

Italy
 
Agent: computer-assisted cognitive rehabilitation
Treatment Mode of Action: To improve memory, attention
Study Description/Purpose: Randomized, double-blind study
Institution(s): Multiple sites
Type of MS: all
Number of Subjects: 120
Funding: National MS Society
Enrollment Information: Alessandra Solari, MD, solari@istituto-esta.it